Wazzup ResApp?

This post represents the first in a series of THREE posts that I have written at the request of readers. After my slightly sarcastic review of iSonea¬†where I sort of lumped iSonea and ResApp together in to the “turd” category, but without any real elaboration, I had several requests for clarification. Incidentally, I appreciate it…

No Delirium in Adherium

Well, by now, the cat is out of the bag… and we know that Adherium successfully raised $35m in an oversubscribed share offer, and will list on the ASX (subject to regulator approval) on the 26th of August. It’s sort of nice to see our brethren from across the Tasman come up with something innovative…

ISN : iSonearlythere…

What a stupid company. I always thought it was beneath me to comment on this company, it’s truly that bad. But when I saw today’s ASX announcement about iSonea’s “second generation” wheeze monitor (a “Wheezometer” no less…), I just had to comment. Briefly. Not much more than a quick wheeze, I promise. Now, I don’t…

The Incest of ASX Biopharma

It’s pretty hard to beat the Brits when it comes to situational comedy. As a dual-Australian/Canadian national educated in the UK, I suppose I have an intrinsic affinity for that dry, offhand style of humour. A few years ago, I stumbled across a brilliant comedy skit that visually captures precisely the fundamental reason why ASX biopharma is…